添加链接
link管理
链接快照平台
  • 输入网页链接,自动生成快照
  • 标签化管理网页链接

何媛, 杜莹, 张俐鹏, 陈敬, 许斌. 替罗非班的输注策略对冠状动脉内膜剥脱术后出血的影响[J]. 中华损伤与修复杂志(电子版), 2022, 17(02): 135-140.

Yuan He, Ying Du, Lipeng Zhang, Jing Chen, Bin Xu. Effect of tirofiban infusion strategy on hemorrhage after coronary endarterectomy[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2022, 17(02): 135-140.

目的

探讨替罗非班的输注方式对冠状动脉内膜剥脱术(CE)术后患者出血的影响。

方法

选入2020年6月至2021年5月在首都医科大学附属北京安贞医院行CE手术患者69例,根据术后患者输注替罗非班方式不同分为应用可调节静脉输液器组(45例)和应用静脉输液泵组(24例),前者采用带有刻度(滚轮或滑轮)输液器,后者采用精密静脉输液泵进行临床治疗:比较2组患者术后替罗非班的输注速度、术后第1天出血量、术后第2天出血量、术后第3天出血量、术后第1天凝血四项检测结果、术后第1天肌钙蛋白检测结果等指标。数据比较采用独立样本 t 检验或秩和检验、 χ 2 检验,采用线性回归模型分析术后出血量与凝血指标的相关性。

结果

静脉输液泵组患者术后第1、2天出血量为(472.6±233.6)mL、215.0 (152.5, 300.0) mL,均显著低于可调节静脉输液器组患者[(1 134.8±317.8) mL、480.0 (350.0, 600.0) mL],差异均有统计学意义( t =8.97, Z =-5.81; P <0.05);可调节静脉输液器组患者术后第1天活化部分凝血活酶时间(APTT)为(33.3±0.4)s,显著高于静脉输液泵组患者[(29.5±3.1)s],差异有统计学意义( Z =-4.66, P <0.05);2组患者术后替罗非班输注速度、术后肌钙蛋白、凝血酶原时间、纤维蛋白原和D二聚体比较差异均无统计学意义( P >0.05);线性回归分析显示术后第1天出血量和术后第2天出血量均与术后第1天APTT存在显著线性关系( R 2 =0.77、0.49, P <0.05)。

结论

应用可调节静脉输液器输注替罗非班的CE术后患者APTT显著升高,增加患者术后出血量,而使用静脉输液泵输注替罗非班可显著提高术后安全性。

Objective

To explore the effect of tirofiban infusion mode on the hemorrhage of patients after coronary endarterectomy (CE).

Methods

Sixty-nine patients who underwent CE operation in Beijing Anzhen Hospital, Capital Medical University from June 2020 to May 2021 were included. According to the different infusion methods of tirofiban, the patients were divided into two groups: the application of adjustable intravenous infusion device group (45 cases) and the application of amedrop group (24 cases). The former used the infusion device with scale (roller or pulley), and the latter used the precision amedrop for clinical treatment. The postoperative infusion speed of tirofiban, blood loss on the first, second and third day after surgery were recorded and analyzed, the results of four coagulation tests and troponin detection on the first day after surgery, and other indicators were compared between the two groups. The data were compared by independent sample t -test, rank sum test and chi-square test, and linear regression model was used to analyze the correlation between postoperative blood loss and coagulation indicators.

Results

The blood loss on the first day and the second day after operation in the amedrop group were (472.6±233.6)mL and 215.0 (152.5, 300.0) mL respectively, which were lower than those in the adjustable intravenous infusion set group [(1 134.8±317.8)mL、480.0 (350.0, 600.0) mL], the differences were statistically significant( t =8.97, Z =-5.81; P <0.05). The activated partial thromboplastin time (APTT) on the first day after operation in the adjustable intravenous infusion set group was (33.3±0.4) s, which was higher than that in the amedrop group[ (29.5±3.1) s], the difference was statistically significant( Z =-4.66, P < 0.05). There was no significant difference in tirofiban infusion rate, postoperative troponin, prothrombin time, fibrinogen and D dimer between the two groups ( P > 0.05). Linear regression analysis showed that there was a significant linear correlation between the blood loss on the first day and second day after operation and APTT on the first day after operation ( R 2 = 0.77, 0.49; P <0.05).

Conclusion

The APTT and postoperative blood loss of CE patients after infusion of tirofiban with adjustable intravenous infusion device are significantly increased, while the infusion of tirofiban with amedrop can significantly improve perioperative safety of patients underwent CE.

Key words: Coronary artery disease, Coronary endarterectomy, Tirofiban, Postoperative blood loss, Drug infusion strategy
组别 例数 平均年龄(岁, ± s ) 体重(kg, ± s ) HDL(mmol/L, ± s ) LDL(mmol/L, ± s ) TG(mmol/L, ± s )
可调节静脉输液器组 45 62.5±8.6 73.4±14.1 1.1±0.3 2.3±0.8 1.5±0.6
静脉输液泵组 24 62.3±5.7 75.5±6.9 1.0±0.2 2.1±0.6 1.5±0.9
t / Z / χ 2 0.06 -0.39 0.70 0.51 -0.10
P 0.95 0.70 0.49 0.62 0.92
组别 例数 TNI(pg/mL, ± s ) APTT(s, ± s ) PT(s, ± s ) FBG(g/L, ± s ) D二聚体(ng/mL, ± s )
可调节静脉输液器组 45 7.7±0.3 31.2±2.5 11.6±1.2 3.2±0.7 131.0±24.0
静脉输液泵组 24 6.9±0.7 29.6±3.4 11.6±0.7 2.9±0.7 93.0±58.8
t/Z/χ 2 -0.29 1.33 -0.06 1.00 -0.52
P值 0.77 0.20 0.95 0.33 0.61
组别 例数 男性占比[例(%)] 冠状动脉介入史[例(%)] 高血压病[例(%)] 糖尿病[例(%)] 心梗史[例(%)]
可调节静脉输液器组 45 39 (86.6) 9 (20.0) 23 (51.1) 27 (60.0) 9 (20.0)
静脉输液泵组 24 18 (75.0) 6 (25.0) 18 (75.0) 16 (66.7) 6 (25.0)
t / Z / χ 2 1.48 0.23 3.70 0.30 0.23
P 0.32 0.76 0.07 0.61 0.76
组别 例数 平均年龄(岁, ± s ) 体重(kg, ± s ) HDL(mmol/L, ± s ) LDL(mmol/L, ± s ) TG(mmol/L, ± s )
可调节静脉输液器组 45 62.5±8.6 73.4±14.1 1.1±0.3 2.3±0.8 1.5±0.6
静脉输液泵组 24 62.3±5.7 75.5±6.9 1.0±0.2 2.1±0.6 1.5±0.9
t / Z / χ 2 0.06 -0.39 0.70 0.51 -0.10
P 0.95 0.70 0.49 0.62 0.92
组别 例数 TNI(pg/mL, ± s ) APTT(s, ± s ) PT(s, ± s ) FBG(g/L, ± s ) D二聚体(ng/mL, ± s )
可调节静脉输液器组 45 7.7±0.3 31.2±2.5 11.6±1.2 3.2±0.7 131.0±24.0
静脉输液泵组 24 6.9±0.7 29.6±3.4 11.6±0.7 2.9±0.7 93.0±58.8
t/Z/χ 2 -0.29 1.33 -0.06 1.00 -0.52
P值 0.77 0.20 0.95 0.33 0.61
组别 例数 男性占比[例(%)] 冠状动脉介入史[例(%)] 高血压病[例(%)] 糖尿病[例(%)] 心梗史[例(%)]
可调节静脉输液器组 45 39 (86.6) 9 (20.0) 23 (51.1) 27 (60.0) 9 (20.0)
静脉输液泵组 24 18 (75.0) 6 (25.0) 18 (75.0) 16 (66.7) 6 (25.0)
t / Z / χ 2 1.48 0.23 3.70 0.30 0.23
P 0.32 0.76 0.07 0.61 0.76
组别 例数 药物输注速度(mL/h, ± s ) 术后第1天出血量(mL, ± s ) 术后第2天出血量(mL, IQR ) 术后第3天出血量(mL, IQR )
可调节静脉输液器组 45 13.4±2.3 1 134.8±317.8 480.0 (350.0, 600.0) 100.0 (100.0, 150.0)
静脉输液泵组 24 13.6±1.3 472.6±233.6 215.0 (152.5, 300.0) 100.0 (52.5, 137.5)
t / Z -0.36 8.97 -5.81 -1.18
P 0.91 <0.05 <0.05 0.24
组别 例数 TNI( pg/mL, ± s ) APTT(s, ± s ) PT(s, ± s ) FBG(g/L, ± s ) D二聚体(ng/mL, ± s )
可调节静脉输液器组 45 4.0±1.8 33.3±0.4 14.3±1.8 3.1±1.1 229.0±39.0
静脉输液泵组 24 6.9±1.4 29.5±3.1 14.0±0.9 2.9±0.9 139.0±29.1
t / Z -0.55 -4.66 0.45 0.29 -1.36
P 0.58 <0.05 0.66 0.78 0.18
组别 例数 药物输注速度(mL/h, ± s ) 术后第1天出血量(mL, ± s ) 术后第2天出血量(mL, IQR ) 术后第3天出血量(mL, IQR )
可调节静脉输液器组 45 13.4±2.3 1 134.8±317.8 480.0 (350.0, 600.0) 100.0 (100.0, 150.0)
静脉输液泵组 24 13.6±1.3 472.6±233.6 215.0 (152.5, 300.0) 100.0 (52.5, 137.5)
t / Z -0.36 8.97 -5.81 -1.18
P 0.91 <0.05 <0.05 0.24
组别 例数 TNI( pg/mL, ± s ) APTT(s, ± s ) PT(s, ± s ) FBG(g/L, ± s ) D二聚体(ng/mL, ± s )
可调节静脉输液器组 45 4.0±1.8 33.3±0.4 14.3±1.8 3.1±1.1 229.0±39.0
静脉输液泵组 24 6.9±1.4 29.5±3.1 14.0±0.9 2.9±0.9 139.0±29.1
t / Z -0.55 -4.66 0.45 0.29 -1.36
P 0.58 <0.05 0.66 0.78 0.18
彭冠华, 张建琴, 钟龙和, 李莎莎, 唐颖, 刘俭, 吴爵非. 负荷超声心动图联合心肌声学造影评估缺血性心脏病患者临床预后的价值 [J]. 中华医学超声杂志(电子版), 2022, 19(12): 1342-1348. 陈春晖, 傅宴, 张源祥, 邱银汝, 梁志尧, 谢薇, 刘福秀. 三磷酸腺苷负荷超声造影在冠状动脉痉挛诊断中的应用 [J]. 中华医学超声杂志(电子版), 2022, 19(02): 161-169. 呙登俊, 潘勇, 余自强, 张震中. 急性缺血性脑卒中取栓治疗后联用替罗非班静脉维持的临床研究 [J]. 中华危重症医学杂志(电子版), 2022, 15(03): 205-209. 庞慧, 杨浩, 付强, 郭鹏, 纵振坤. CHA 2 DS 2 -VASc评分在高血压合并冠心病患者脑卒中风险预测中的应用 [J]. 中华神经创伤外科电子杂志, 2022, 08(02): 69-75. 陈捷, 周峰, 刘金波, 王宏宇. 基于聚类的冠心病患者药物治疗模式及人群异质性研究 [J]. 中华临床医师杂志(电子版), 2022, 16(10): 1012-1018. 唐红燕, 丹海俊, 高志红, 张作阳, 翟书梅, 吴少玉, 张玉. 心脏彩色多普勒超声在冠心病慢性心力衰竭患者临床诊断中的应用 [J]. 中华临床医师杂志(电子版), 2022, 16(07): 676-679. 蔡琦, 雍永宏, 何花, 佘铜生, 俞慧. 三维斑点追踪技术联合血清同型半胱氨酸对冠心病患者左心功能的评估价值 [J]. 中华临床医师杂志(电子版), 2022, 16(05): 425-430. 陈慧娟, 陈然, 金平, 吴章松, 刘勇, 徐菲, 赵启媛. 口服阿司匹林联合替罗非班对老年进展性缺血性脑卒中患者功能转归的影响 [J]. 中华临床医师杂志(电子版), 2021, 15(12): 922-927. 韩壮, 贾振宇, 吴文涛, 赵林波, 刘圣, 施海彬. 短期加用替罗非班在支架辅助弹簧圈栓塞梭形动脉瘤中的安全性与有效性研究 [J]. 中华介入放射学电子杂志, 2022, 10(01): 11-15. 郭义城, 谢志鹏, 刘万里, 赵阳, 车艳生, 赵敏. 胸12椎体骨质疏松性椎体压缩骨折致心前区牵涉痛误诊为冠心病特征分析 [J]. 中华诊断学电子杂志, 2023, 11(02): 136-139. 叶宽萍, 李花, 马晓文, 刘晓燕, 陈凤玲. 2型糖尿病患者血尿酸水平与Framingham十年冠心病发生风险的关系研究 [J]. 中华诊断学电子杂志, 2022, 10(03): 145-151. 郭少华, 耿世佳, 洪申达, 穆冠宇, 张一芝, 杨磊, 刘彤, 陈康寅. 人工智能辅助心电图识别无冠心病人群的临床研究 [J]. 中华心脏与心律电子杂志, 2023, 11(01): 18-23. 张海凤, 周梦竹, 霍宁, 陈砚戈, 富华颖, 刘彤, 李广平, 刘长乐. 漂浮导管监测下的介入治疗在高危重症冠心病患者中的应用 [J]. 中华心脏与心律电子杂志, 2022, 10(04): 209-214. 肖懿慧, 袁祖贻. 冠心病合并抑郁:我们要做什么 [J]. 中华心脏与心律电子杂志, 2022, 10(04): 193-196. 冯永拿, 唐婷玉, 吕方超, 陈岚. 小气道功能与老年冠心病的相关性 [J]. 中华老年病研究电子杂志, 2022, 09(03): 17-20.